Genetic testing to find BRCA 1/2 mutation for detecting breast and ovarian cancer
NGenebio
Reagents
Detecting breast and ovarian cancer
BRCAaccuTest™ PLUS with CE-IVD certificate for HBOC Breast/Ovarian Cancer Test
Genetic testing to find BRCA 1/2 mutation for detecting breast and ovarian cancer
BRCAaccuTest™ PLUS | ||
---|---|---|
Certification | CE-IVD | |
Target Gene | Breast Cancer/Ovarian cancer HBOC (Hereditary breast and ovarian cancer syndrome) |
|
Treatment-enhancing methods | Method of Amplicon | |
Numbers | 12 (6+6) tests (1 tests for DNA control) |
24 tests (1 tests for DNA control) |
Samples | Blood, FFPE, biopsy tissue | |
Amount of DNA input | 10-30 ng | |
Target Gene | BRCA1 / BRCA2 | |
Target Area | 22.4 kb (all protein coding zones, joins, startup zones selected, UTR, intron regions) | |
amplicon | 160 (2 pools) | |
Timing | >5 hrs | |
Variant | SNV, In, Del, Dup, CNV* | |
NGS platform & reagent | illumina MiSeq, MiSeq Dx / MiSeq Reagent Nano, Micro kit, v2, 300cycles | |
Throughput Sample | Germline (11) / Somatic (5) | Germline (23) |
Analysis Solution | NGeneAnalySys™ (CE) |
*CNV: Only ROU
Supplier
Ngenebio
The EntroGen NGS Targeted Hotspot Panel is a comprehensive assay that detects clinically relevant mutations in solid tumors using next-generation sequencing, compatible with fresh frozen and FFPE samples. It offers high sensitivity, low DNA input, and the ability to batch up to 12 samples in a single run, making it ideal for labs with limited sample volumes.
EntroGen’s BRCA Complete™ Expanded Panel is a comprehensive NGS solution that detects both germline and somatic mutations in genes like BRCA1, BRCA2, CHEK2, PALB2, RAD51C, and TP53 with high sensitivity and specificity. Compatible with blood, fresh frozen, and FFPE samples, the panel reduces allele dropouts and off-target reads using a tiled amplicon PCR approach. It includes reagents for library preparation and user-friendly software for easy mutation identification, along with quality control assays to ensure high-quality data without repeat sequencing.
SOLIDaccuTest™ is an excellent tool for discovering variants associated with solid tumors using a comprehensive approach to next-generation sequencing (NGS). It reflects the latest research trends and is optimized for medical purposes by selecting essential genes of solid tumors including lung, colon, breast, skin brain, stomach and ovarian cancers, etc.
SOLIDaccuTest™ is an excellent tool to explorer variants associated with solid tumors using a comprehensive method of next-generation sequencing (NGS). It reflects the latest research trends and is optimized for the medical purpose by selecting essential genes of solid tumors including lung, colon, breast, skin brain, gastric, ovarian cancers, etc.
BRCAaccuTest™ & BRCAaccuTest™PLUS is a regent for producing libraries for
analyzing the BRCA ½ genes using the NGS (next-generation sequencing) method,
which analyzes genomic DNA derived from blood or FFPE tissues.
The NextSeq 2000 Sequencing System uses patterned flow cells similar to those that power the NovaSeq™ 6000 System. The result is a highly flexible and scalable benchtop system that offers the highest cluster density flow cell of any on-market NGS system to date, driving down the cost per gigabase (Gb) of the sequencing run.
Model: NextSeq 1000
Manufacturer: Illumina
Origin: Singapore/United States
Launching year: 01/2020
PANA RealTyperTM HPV Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC.
DxFLEX is a new clinical flow cytometry platform derived from the successful CytoFLEX. The advanced sensitivity and intuitive software DxFLEX makes flow cytometry routine for both novice and expert flow cytometry technicians and promotes standardization. Functionality in the autoloader facilitates accurate results and sample tracking.
TruSight Tumor 26 Kit includes library preparation reagent set and uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 26 genes that are commonly related to mutations in solid tumors and somatic variants